40 Hz Gamma Entrainment (GENUS Protocol) — Cognitive Technologies & Brain Longevity
MIT-developed light and sound flickering at 40 Hz to entrain gamma brainwaves — reduces amyloid and tau in mouse models, Phase 2 human trials underway for Alzheimer's prevention.
Overview
GENUS (Gamma Entrainment Using Sensory Stimuli) is a non-invasive approach developed by Li-Huei Tsai and Edward Boyden at MIT PICOWER Institute. Research began when they discovered that optogenetically driving fast-spiking interneurons at 40 Hz (gamma frequency) in Alzheimer's mouse models dramatically reduced amyloid plaques and tau tangles and improved cognitive function. They then found that simply exposing mice to 40 Hz light flickering (LED lights flickering at 40 Hz) — invisible to the eye above ~30 Hz — was sufficient to entrain gamma oscillations in the visual cortex and produce the same benefits. Adding 40 Hz sound (clicking at 40 Hz) entrained gamma across auditory cortex and hippocampus. The Nature 2016 paper caused enormous excitement; a 2019 Cell paper showed combined auditory-visual stimulation extended the effect systemically. Human Phase 2 trial (OVERTURE, n=76, Cognito Therapeutics) found 6 months of 40 Hz light and sound stimulation reduced amyloid burden on PET scan and hippocampal atrophy rate versus sham. Cognito Therapeutics has received FDA Breakthrough Device Designation for their Spectris device. Humans cannot consciously detect 40 Hz flicker — the device appears as steady light while the brain unconsciously responds to the gamma drive.
Indications
- Alzheimer's disease prevention and early-stage treatment (Phase 2 human evidence)
- Mild cognitive impairment (MCI) intervention
- Proactive brain aging prevention and gamma maintenance
- Neuroinflammation reduction (human imaging evidence)
Mechanism of Action
Visual cortex neurons naturally entrain their firing rate to periodic visual stimuli — 40 Hz flickering drives visual cortical neurons to fire synchronously at gamma frequency, propagating through cortical-hippocampal circuits
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Cognito Therapeutics Spectris (clinical device) | 40 Hz audio-visual stimulation, 1 hour per day | Daily | Clinical trial device; not yet commercially available; Phase 2 OVERTURE trial results showed amyloid reduction; FDA Breakthrough Designation |
| DIY 40 Hz light (research context) | 40 Hz LED flickering (e.g., YouTube 40 Hz binaural/flicker videos or DIY LED driver) | 1 hour daily | Consumer devices not validated; frequency accuracy varies; binaural beats at 40 Hz have different (disputed) mechanism from actual 40 Hz flicker; use only validated approach |
Evidence Grade
GRADE B
Safety & Contraindications
- Generally safe: no serious adverse events in Phase 2 trials
- Photosensitive epilepsy contraindication: although 40 Hz is above typical photosensitive flicker frequencies (3-30 Hz), caution warranted; consult neurologist
- Headache or visual discomfort reported by minority of participants
- Must not use commercial consumer flickering devices without clinical guidance — frequency accuracy critical
- Cognito Therapeutics Spectris device is the only validated commercial system under FDA breakthrough designation